10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone. However, tenofovir disoproxil fumarate is associated with renal and bone toxic effects; the novel prodrug tenofovir alafenamide achieves 90% lower plasma tenofovir concentrations. We aimed to further assess safety and efficacy of fixed-dose combination emtricitabine with tenofovir alafenamide in patients switched from emtricitabine with tenofovir disoproxil fumarate.

          Related collections

          Author and article information

          Journal
          Lancet HIV
          The lancet. HIV
          Elsevier BV
          2352-3018
          2352-3018
          Apr 2016
          : 3
          : 4
          Affiliations
          [1 ] Southwest CARE Center, Santa Fe, NM, USA.
          [2 ] Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
          [3 ] CMIT, Paris, France.
          [4 ] Central Texas Clinical Research, Austin, TX, USA.
          [5 ] Peter J Ruane MD Inc, Los Angeles, CA, USA.
          [6 ] Orlando Immunology Center, Orlando, FL, USA.
          [7 ] Royal Free London NHS Foundation Trust, London, UK.
          [8 ] CHU Saint-Pierre University Hospital, Brussels, Belgium.
          [9 ] Triple O Research Institute PA, FL, USA.
          [10 ] Dupont Circle Physicians Group, Washington, DC, USA.
          [11 ] Clinical Research Puerto Rico Inc San Juan, Puerto Rico.
          [12 ] Gilead Sciences, Foster City, CA, USA.
          [13 ] Gilead Sciences, Foster City, CA, USA. Electronic address: martin.rhee@gilead.com.
          Article
          S2352-3018(16)00024-2
          10.1016/S2352-3018(16)00024-2
          27036991
          771f130a-e007-428a-a864-72233f207234
          History

          Comments

          Comment on this article

          scite_

          Similar content113

          Cited by54